Biota is an Australian biotechnology company founded in 1985 to further develop the funding of human pharmaceutical discovery and development. Since its inception, Biota has advanced Australian science in the areas of virology and molecular biology, discovering new human pharmaceuticals for the treatment of viral respiratory diseases such as influenza, Rhinovirus and Respiratory Syncytial Virus.
Innovation drives the company.
This is proven as Biota's focus moves towards the development of new and effective drugs for respiratory viral infections. While many Australian biotechnology companies are expanding the breadth of their research portfolios, Biota is focusing in just one area - viral respiratory diseases. This direction has seen Biota recognised as one of the more successful biotechnology companies in Australia following the successful commercialisation of Relenza and FLU OIA . It is the first of a new generation of drugs known as neuraminidase inhibitors. It acts by preventing the spread of infection from one cell to another within the respiratory tract.